Ginsenoside Rg3, a promising agent for NSCLC patients in the pandemic: a large-scale data mining and systemic biological analysis

• DOI: 10.1016/j.jgr.2022.09.006
• Publication Date: 2022-10-12T08:46:13Z
• Authors: Zhenjie Zhuang; Qianying Chen; Xiaoying Zhong; Huiqi Chen; Runjia Yu; Ying Tang
• Keywords: Ginsenoside Rg3; 0303 health sciences; 03 medical and health sciences; Non-small cell lung cancer; QK1-989; Biological analysis; Botany; Systemic computational biology; Coronavirus Disease-2019; Research Article; 3. Good health

Non-small cell lung cancer (NSCLC) patients are particularly vulnerable to the Coronavirus Disease-2019 (COVID-19). Currently, no anti-NSCLC/COVID-19 treatment options available. As ginsenoside Rg3 is beneficial NSCLC and has been identified as an entry inhibitor of virus, this study aims explore underlying pharmacological mechanisms for with COVID-19.Based on a large-scale data mining systemic biological analysis, investigated target genes, processes, mechanisms, immune implications COVID-19.An important gene set containing 26 genes was built. Target significant prognostic value were identified, including baculoviral IAP repeat 5 (BIRC5), carbonic anhydrase 9 (CA9), endothelin receptor type B (EDNRB), glucagon (GCGR), interleukin 2 (IL2), peptidyl arginine deiminase 4 (PADI4), solute carrier organic anion transporter family member 1B1 (SLCO1B1). The expression significantly correlated infiltration level macrophages, eosinophils, natural killer cells, T lymphocytes. Ginsenoside may benefit COVID-19 by regulating signaling pathways primarily involved in anti-inflammation, immunomodulation, cycle, fate, carcinogenesis, hemodynamics.This provided comprehensive strategy drug discovery based biology approaches. be prospective COVID-19. Future studies needed determine